Previous 10 | Next 10 |
The Renaissance IPO Index rose 2.8% on Monday, and surpassed its all-time high in mid-day trading. The IPO Index is now up 12.9% for the year , outperforming the S&P 500 by 20 points, and the Nasdaq Composite by 10 points. The Renaissance IPO ETF (IPO) tracks the index, which is compo...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are advised to contact KSF Managing Partner Lewis K...
After soaring on Monday, cruise ship stocks pulled back a bit on Tuesday. Shares of Carnival (NYSE: CCL) , Royal Caribbean (NYSE: RCL) , and Norwegian Cruise Line Holdings (NYSE: NCLH) fell 4.1%, 3.6%, and 3.5%, respectively. Following reassuring comments by Federal Reserve Chair...
Biotech and COVID-19 darling Moderna ( MRNA -9.5% ) is surrendering some its recent gains on almost triple normal volume. More news on: Moderna, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Tiny sprinkles of positive trial data regarding a SARS-CoV-2 vaccine candidate have inspired Wall Street analysts to hike their stock price targets for its creator, Moderna (NASDAQ: MRNA) . The most enthusiastic investment bank price target hike so far, $112 from BMO Capital on Tuesday, sugge...
May 19, 2020 Palm Beach, FL – May 19, 2020 – The global science community is arguably facing one of its greatest challenges yet in the current global healthcare crisis. Article after article demonstrates that the global pandemic is causing the breakdown of soci...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . While U.S. consumers didn't do much shopping in April, considering last Friday's dreadful retail sales report, investors might soo...
Deciphera Receives FDA Approval for GIST Therapy Deciphera Pharmaceuticals ( DCPH ) reported that it has received an early FDA approval for Qinlock for treating patients with gastrointestinal stromal tumor (GIST). The treatment is specifically targeted at patients who did not response to...
( Pexels ) Next to technology, healthcare has been the top-performing sector so far this year. Equities in the sector saw moderate declines during the March crash as investors discount higher revenue for many firms. Since the market's March lows, the Health Care Select Sect SPDR ETF's ( XLV ...
Moderna (NASDAQ: MRNA ) has priced its public offering of 17.6M common shares at $76.00 per share, for gross proceeds of $1.34B. More news on: Moderna, Inc., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
On CNBC's “Mad Money Lightning Round,” Jim Cramer believes in Moderna, Inc. (NASDAQ:MRNA). On May 14, Evercore ISI Group analyst C...
2024-05-14 06:35:00 ET Investors have put their hopes in Moderna 's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it represents a new revenue stream for a company that until now has relied on just one product, and a product strugg...